New research has shown that ultrasmall Cornell Prime Dots, or C’Dots, which are among the nanocarriers for therapeutics once thought to be viable only by injection, have the potential to be administered orally.
Read the story in the Cornell Chronicle.
Twenty-three Receive Awards Recognizing Excellence and Impact
Cornell University Graduate School
